Literature DB >> 8530408

Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic beta cells. Enhanced insulin secretion in CD38-expressing transgenic mice.

I Kato1, S Takasawa, A Akabane, O Tanaka, H Abe, T Takamura, Y Suzuki, K Nata, H Yonekura, T Yoshimoto.   

Abstract

Cyclic ADP-ribose (cADPR) serves as a second messenger for Ca2+ mobilization in insulin secretion, and CD38 has both ADP-ribosyl cyclase and cADPR hydrolase activities (Takasawa, S., Tohgo, A., Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Yonekura, H., and Okamoto, H. (1993) J. Biol. Chem. 268, 26052-26054). Here, we produced transgenic mice overexpressing human CD38 in pancreatic beta cells. The enzymatic activity of CD38 in transgenic islets was greatly increased, and ATP efficiently inhibited the cADPR hydrolase activity. The Ca2+ mobilizing activity of cell extracts from transgenic islets incubated in high glucose was 3-fold higher than that of the control, suggesting that ATP produced by glucose metabolism increased cADPR accumulation in transgenic islets. Glucose- and ketoisocaproate-induced but not tolbutamide- nor KCl-induced insulin secretions from transgenic islets were 1.7-2.3-fold higher than that of control. In glucose-tolerance tests, the transgenic serum insulin level was higher than that of control. The present study provides the first evidence that CD38 has a regulatory role in insulin secretion by glucose in beta cells, suggesting that the Ca2+ release from intracellular cADPR-sensitive Ca2+ stores as well as the Ca2+ influx from extracellular sources play important roles in insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530408     DOI: 10.1074/jbc.270.50.30045

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  Multiple signal transduction pathways mediated by 5-HT receptors.

Authors:  Mami Noda; Haruhiro Higashida; Shunsuke Aoki; Keiji Wada
Journal:  Mol Neurobiol       Date:  2004-02       Impact factor: 5.590

2.  Nicotinic acid-adenine dinucleotide phosphate-sensitive calcium stores initiate insulin signaling in human beta cells.

Authors:  James D Johnson; Stanley Misler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

3.  The CD38-cyclic ADP-ribose signaling system in insulin secretion.

Authors:  H Okamoto
Journal:  Mol Cell Biochem       Date:  1999-03       Impact factor: 3.396

4.  Human CD38 is an authentic NAD(P)+ glycohydrolase.

Authors:  V Berthelier; J M Tixier; H Muller-Steffner; F Schuber; P Deterre
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

Review 5.  CD38 autoimmunity: recent advances and relevance to human diabetes.

Authors:  A Antonelli; E Ferrannini
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

6.  Expression of CD38 with intracellular enzymatic activity: a possible explanation for the insulin release induced by intracellular cADPR.

Authors:  Yasuhiko Ohta; Akira Kitanaka; Keichiro Mihara; Osamu Imataki; Hiroaki Ohnishi; Terukazu Tanaka; Tomohiko Taminato; Yoshitsugu Kubota
Journal:  Mol Cell Biochem       Date:  2011-03-09       Impact factor: 3.396

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  TRPM2 functions as a lysosomal Ca2+-release channel in beta cells.

Authors:  Ingo Lange; Shinichiro Yamamoto; Santiago Partida-Sanchez; Yasuo Mori; Andrea Fleig; Reinhold Penner
Journal:  Sci Signal       Date:  2009-05-19       Impact factor: 8.192

Review 9.  Anti-CD38 autoantibodies in type? diabetes.

Authors:  Roberto Mallone; Paolo Cavallo Perin
Journal:  Diabetes Metab Res Rev       Date:  2006 Jul-Aug       Impact factor: 4.876

10.  Autoantibodies against CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) that impair glucose-induced insulin secretion in noninsulin- dependent diabetes patients.

Authors:  F Ikehata; J Satoh; K Nata; A Tohgo; T Nakazawa; I Kato; S Kobayashi; T Akiyama; S Takasawa; T Toyota; H Okamoto
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.